Oric Pharmaceuticals Inc at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) Transcript

Feb 10, 2022 / 07:00PM GMT
Michael Schmidt - Guggenheim Partners, LLC - Analyst

All right. Hello, and welcome. My name is Michael Schmidt. I'm a Biotech Analyst with Guggenheim, and it's my great pleasure to welcome the ORIC team. With us today, we have Jacob Chacko, CEO; as well as Dominic Piscitelli, Chief Financial Officer. Welcome, guys. Thanks for joining us.

Jacob Chacko - ORIC Pharmaceuticals, Inc. - CEO

Thanks for having us, Michael.

Questions and Answers:

Michael Schmidt - Guggenheim Partners, LLC - Analyst

Yes. So Jacob, ORIC has a diverse portfolio of oncology drugs and then an interesting history, I think. Just remind us of the overall business model, and guiding principles of each strategy?

Jacob Chacko - ORIC Pharmaceuticals, Inc. - CEO

Sure thing, Michael. As you mentioned, I think we have one of the most robust pipelines of oncology therapeutics in small-cap biotech today. There's a couple things that I think makes us unique. One is that we've got the full slate of internal
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot